Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide with Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
NCT02138383Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- May 2014
- Primary completion
- Dec 2016
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enzalutamide in pancreatic adenocarcinoma (PDAC), sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose at 18 months. Started May 2014; status: completed.
02
Drugs
enzalutamide
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02138383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02138383.